Optimizing diagnosis in Parkinson's disease: Radionuclide imaging
Authors:
- 1 January 2016
- journal article
- review article
- Published by Elsevier in Parkinsonism & Related Disorders
- Vol. 22, S47-S51
Abstract
No abstract availableKeywords
Funding Information
- Canadian Institutes of Health Research
- Cundill Foundation
- Michael J. Fox Foundation
- Michael Smith Health Research BC
- Pacific Alzheimer Research Foundation
- Pacific Parkinson's Research Institute
This publication has 30 references indexed in Scilit:
- The Significance of α-Synuclein, Amyloid-β and Tau Pathologies in Parkinson's Disease Progression and Related DementiaNeurodegenerative Diseases, 2013
- Binding of the Radioligand SIL23 to α-Synuclein Fibrils in Parkinson Disease Brain Tissue Establishes Feasibility and Screening Approaches for Developing a Parkinson Disease Imaging AgentPLOS ONE, 2013
- Adenosine 2A receptor availability in dyskinetic and nondyskinetic patients with Parkinson diseaseNeurology, 2011
- Staging of serotonergic dysfunction in Parkinson's Disease: An in vivo 11C-DASB PET studyNeurobiology of Disease, 2010
- Olfactory dysfunction, central cholinergic integrity and cognitive impairment in Parkinson's diseaseBrain, 2010
- History of falls in Parkinson disease is associated with reduced cholinergic activityNeurology, 2009
- Longitudinal progression of sporadic Parkinson's disease: a multi-tracer positron emission tomography studyBrain, 2009
- Visualizing vesicular dopamine dynamics in Parkinson's diseaseSynapse, 2009
- PET in LRRK2 mutations: comparison to sporadic Parkinson's disease and evidence for presymptomatic compensationBrain, 2005
- Microglial activation and dopamine terminal loss in early Parkinson's diseaseAnnals of Neurology, 2005